Ignite Creation Date:
2025-12-24 @ 1:03 PM
Ignite Modification Date:
2026-02-10 @ 7:14 PM
Study NCT ID:
NCT02674061
Status:
COMPLETED
Last Update Posted:
2022-03-24
First Post:
2016-02-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-02-25
Start Date Type:
ACTUAL
Primary Completion Date:
2019-09-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-03-18
Completion Date Type:
ACTUAL
First Submit Date:
2016-02-02
First Submit QC Date:
None
Study First Post Date:
2016-02-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-09-01
Results First Submit QC Date:
None
Results First Post Date:
2020-09-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-23
Last Update Post Date:
2022-03-24
Last Update Post Date Type:
ACTUAL